Investigating high doses of Rifapentine for treating tuberculosis in pregnant women
Official title: Rifapentine in High Doses in Pregnancy with TB (Radiant-Moms) study
Funded at Columbia University Health Sciences · NIH-11009318 · Data updated 2026-11-12
This study is looking at how to safely treat tuberculosis in pregnant and breastfeeding people, especially those who also have HIV, and it wants to understand what treatment options they and their doctors prefer so that everyone can get the best care possible.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 20, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $166,541 |
| NIH project number | 1R21AI186928-01 |
| Project ID | NIH-11009318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pregnant or breastfeeding individuals who are at risk of or diagnosed with tuberculosis.
✕Less likely to help
Patients who are not pregnant or breastfeeding, or those without a TB diagnosis, may not benefit from this research.
What this research studies
This research focuses on the increased risk of tuberculosis (TB) during and after pregnancy, particularly among those co-infected with HIV. It aims to gather data on the safety and dosing of a new TB treatment regimen for pregnant and breastfeeding individuals, who are often excluded from clinical trials. By using a discrete choice experiment, the study will explore the preferences of pregnant people and healthcare providers regarding TB treatment options. The goal is to ensure that pregnant individuals have access to effective TB treatments that are safe for both them and their developing fetus.
Why it matters
Potential benefit: If successful, this research could lead to improved TB treatment options for pregnant women, reducing mortality and adverse outcomes associated with TB and HIV.
How similar studies have gone: While there is a consensus on the need for including pregnant individuals in TB trials, this specific approach to studying high-dose Rifapentine in this population is relatively novel.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Hirsch-Moverman, Yael R — Columbia University Health Sciences
- Study coordinator: Hirsch-Moverman, Yael R
Related research
Other NIH-funded projects on the same topics.
-
How air pollution during pregnancy affects fetal growth over time
This study looks at how air pollution affects the growth of babies in the womb during pregnancy, using ultrasound images to track changes over time, and it aims to help expectant parents understand when their babies might be most at risk from pollution.
-
Postoperative Pain Guidelines for Pregnancy: Safer, Patient-Centered Opioid Use
We’re creating patient-friendly guidelines to help doctors manage pain after delivery and surgery in pregnant people, aiming to reduce opioid overuse and improve safety.
-
HPV and pregnancy risk: a big study following 1,280 pregnancies
A large pregnancy study at UTMB looks at whether human papillomavirus (HPV) during pregnancy is linked to problems like preterm birth.
-
Understanding how where you live and personal factors during pregnancy affect a child’s risk for obesity and metabolic problems
This project looks at how neighborhood conditions and individual factors during pregnancy may influence a child’s risk of obesity and metabolic health as they grow.
-
Blocking cancer-causing cMYC tricks after pregnancy changes in the breast
Researchers are testing how pregnancy and aging reshape the breast before cancer risk, using patient-reinformed models to see if it changes how dangerous cMYC signals behave.
-
SSRI use during pregnancy: effects on placental blood flow and inflammation
This grant studies how antidepressants (SSRIs) used during pregnancy might affect the placenta and inflammation, and whether a 5-HT2 receptor blocker could mitigate any negative effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.